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Uncovering pathways underlying drug-induced toxicity is a fundamental objective in the field of toxicogenomics.
Developing mechanism-based toxicity biomarkers requires the identification of such novel pathways and the order of
their sufficiency in causing a phenotypic response. Genome-wide RNA interference (RNAi) phenotypic screening has
emerged as an effective tool in unveiling the genes essential for specific cellular functions and biological activities.
However, eliciting the relative contribution of and sufficiency relationships among the genes identified remains
challenging. In the rodent, the most widely used animal model in preclinical studies, it is unrealistic to exhaustively
examine all potential interactions by RNAi screening. Application of existing computational approaches to infer
regulatory networks with biological outcomes in the rodent is limited by the requirements for a large number of
targeted permutations. Therefore, we developed a two-step relay method that requires only one targeted perturbation
for genome-wide de novo pathway discovery. Using expression profiles in response to small interfering RNAs (siRNAs)
against the gene for peroxisome proliferator-activated receptor a (Ppara), our method unveiled the potential causal
sufficiency order network for liver hypertrophy in the rodent. The validity of the inferred 16 causal transcripts or 15
known genes for PPARa-induced liver hypertrophy is supported by their ability to predict non-PPARa–induced liver
hypertrophy with 84% sensitivity and 76% specificity. Simulation shows that the probability of achieving such
predictive accuracy without the inferred causal relationship is exceedingly small (p , 0.005). Five of the most sufficient
causal genes have been previously disrupted in mouse models; the resulting phenotypic changes in the liver support
the inferred causal roles in liver hypertrophy. Our results demonstrate the feasibility of defining pathways mediating
drug-induced toxicity from siRNA-treated expression profiles. When combined with phenotypic evaluation, our
approach should help to unleash the full potential of siRNAs in systematically unveiling the molecular mechanism of
biological events.
Citation: Dai X, De Souza AT, Dai H, Lewis DL, Lee CK, et al. (2007) PPARa siRNA–treated expression profiles uncover the causal sufficiency network for compound-induced
liver hypertrophy. PLoS Comput Biol 3(3): e30. doi:10.1371/journal.pcbi.0030030
Introduction
Determining the pathways underlying drug-induced tox-
icity from genome-wide expression proﬁles is essential for
drug development. Knowledge of the components of the
identiﬁed pathways and their sufﬁciency order for toxicity is
crucial for selecting mechanism-based biomarkers to assess
the safety of novel agents. Numerous efforts have been made
to establish toxicogenomics databases, most of which consist
of thousands of expression proﬁles produced in response to
treatment with dozens or hundreds of compounds and their
associated toxicities [1–5]. Classiﬁers based on genes showing
altered expression in association with the observed toxicities
have been developed to predict a variety of potential
toxicities in target tissues, such as liver, kidney, and heart
[1]. Although these metrics built on different machine
learning algorithms could be useful in estimating the severity
of potential toxicities induced by compounds, the applica-
tions of these classiﬁers in understanding the mechanisms of
drug-induced toxicity are not straightforward. In particular,
this approach is unlikely to distinguish the upstream causal
genes from the downstream responsive genes among all the
genes associated with an induced toxicity. Without knowledge
of the causal sufﬁciency order, designing experiments to test
predicted toxicity in animal models remains difﬁcult.
Genome-wide RNA interference (RNAi) has emerged as an
effective tool in uncovering components of pathways for
speciﬁc cellular functions and biological activities, such as the
innate immune response, the DNA-damage response, Golgi
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siae, Caenorhabditis elegans, and Drosophila [6–12]. However,
eliciting the causal sufﬁciency relationships among identiﬁed
genes for a biological activity is still challenging. Phenotypic
screening by RNAi has successfully identiﬁed regulators of a
gene on a single-gene basis [13]; however, it is unrealistic to
exhaustively examine all potential interactions by concom-
itant perturbations targeting each gene within a pathway,
given the exponential number of potential interactions
between these genes and the phenotype [6–12]. Therefore, a
high-throughput approach to identify the most likely
sufﬁciency order among these genes is critical for the
application of RNAi screening in deﬁning phenotype-
orientated pathways. Such an approach is particularly
important for pathway discovery in rodents, the most
frequently used animal models in preclinical studies. Un-
fortunately, introducing genome-wide targeted genetic mod-
iﬁcations in rodents is technically challenging.
Computational approaches have been reported to infer
regulatory networks from expression proﬁles [14–20]. A
variety of statistical modeling approaches, including Baye-
sian-based networks, graph theory, and ordinary differential
equations, have been used for depicting or uncovering
molecular networks. Collins and colleagues ﬁrst developed a
model for identifying the mode of action for a compound
after perturbing each of the genes in the network [17].
Friedman and colleagues reported a Bayesian network
approach for de novo inference of potential transcriptional
networks based on 300 expression proﬁles obtained from
yeast strains with 276 deletion mutations [18]; this approach
did not require prior knowledge about the modeled network,
as Collins’ approach did. Approaches based on physical
interactions, such as DNA–protein or protein–protein inter-
actions, were reported by Yeang et al., Gifford, and a couple
of other groups as well [20,21]. Although implemented
successfully in S. cerevisiae, these published approaches
depend on the accessibility of genome-wide targeted pertur-
bations in individual model systems. Even in models in which
genome-wide perturbation by genetic engineering can be
easily achieved, such as yeast or ﬂy models, it is still quite
labor intensive and prohibitively expensive to use a genome-
wide overexpression or deletion mutation to obtain the data
required for these analytic approaches. In rodents, it is
unlikely that such a dataset from genome-wide genetic
permutation could be obtained with current technology.
Some progress has been made with the chromatin immuno-
precipitation (ChIP)–chip technology for eliciting potential
transcriptional regulatory relationships; however, screening
for all the transcription factors on the genome scale is
impeded by the lack of speciﬁc antibodies for each of the
known transcription factors.
Recent work by Segal and colleagues in identifying
regulatory modules from ﬁve strains of yeast shows promise
[14,15]. Using precompiled putative transcription factors,
they identiﬁed potential transcriptional modules that are
associated with enriched functionality, suggesting the poten-
tial impact of these genes on certain biological processes.
Others have attempted to associate the derived network with
speciﬁc biological processes as well [18,22–24]. Recent
progress toward identifying a phenotype-oriented network
in rodent models was initially reported by Schadt et al. [23].
Taking advantage of the genetic heterogeneity introduced by
more than 300 crossbreeding F2 mice, the authors inferred
causal genes for obesity from a combination of genetic
quantitative trait loci and their associated expression proﬁles.
The sensitivity and speciﬁcity of their approach depend on
three factors: the frequency of recombination across the
genome, the density of the measured genetic markers, and the
coverage of the phenotypic alteration of interest among the
F2 subpopulations. To ensure adequate statistical power,
their approach requires large-scale cross-breeding and
genotyping, yet it may not be ﬂexible enough for inferring
causal genes for drug-induced toxicities in any target tissue.
To uncover a phenotype-orientated network for any type
of drug-induced toxicity in rodents, we developed a two-step
relay approach to infer causal genes and their sufﬁciency
order from small interfering RNA (siRNA) response expres-
sion proﬁles. In the ﬁrst step, we used both the on- and off-
target effects from RNAi to infer pairwise regulatory
relationships from the expression proﬁles. This strategy
allowed us to avoid the need for large-scale targeted genetic
perturbations required by the majority of previously devel-
oped methods. In the second step, we used the inferred
regulatory relationships among the identiﬁed gene pairs to
derive causal genes for any type of drug-induced toxicity
from any previously established toxicogenomics database in
the rodent. Our approach provides a practical and ﬂexible
strategy for uncovering potential molecular mechanisms for
drug-induced toxicity.
Results
Inferring Pairwise Regulatory Relationships from siRNA-
Treated Expression Profiles
To derive causal genes and their sufﬁciency order in
inducing PPARa activation–induced liver hypertrophy
(AILH), we proﬁled mouse liver after modifying Ppara mRNA
levels by treatment with two Ppara siRNAs [25]. The mRNA
levels of Ppara and two of its known downstream targets,
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Author Summary
Approaches for discovering mechanisms of action and for identify-
ing molecular biomarkers in biomedical research are evolving today,
as the growing symbiosis with computational sciences becomes
more widely appreciated. In fact, the combination of various new
technologies has been pushing forward both frontiers. Here, we
present an example of the combined use of in vivo siRNA knock-
down technology, genome-wide gene expression profiling, and
computational reasoning to unveil regulatory causal relationships
and the sufficiency network of identified genes for compound-
induced toxicity. Unlike previously reported approaches, our
method requires only one targeted perturbation for genome-wide
de novo pathway discovery. Hence, our method can be directly
applied to animal models in which it is still technically challenging to
perform genome-wide genetic perturbation or RNAi screening. The
independent application of our derived model to compounds with
unrelated mechanisms of action suggests the existence of a
universal molecular module that mediates liver hypertrophy. The
resulting sufficiency network for induction of liver hypertrophy will
have an immediate impact on the progress of toxicogenomics.
When combined with phenotypic evaluation, our approach should
help to unleash the full potential of siRNAs in systematically
unveiling the molecular mechanisms of biological events.
Sufficiency Network for Liver Hypertrophycarnitine palmitoyltransferase 1A (Cpt1a) and long-chain acyl-
CoA dehydrogenase (Acadl), were examined in the siRNA-
treated mice as well as in Ppara knockout mice, which served
as a positive control for the silencing efﬁcacy of the Ppara
siRNAs (Figure 1A). Expression of both Ppara and its known
target genes decreased in a coordinated fashion among all
Ppara siRNA–treated mice, and regulation between Ppara and
its targets, Cpt1a and Acadl, was conﬁrmed in the Ppara
knockout mice. These data suggest that Ppara siRNA
effectively downregulates transcription of the targeted gene,
Ppara, and its known downstream genes in vivo. The genome-
wide expression proﬁles in livers from the Ppara siRNA–
treated mice also revealed an extensive off-target effect when
compared with the proﬁles in livers from the Ppara knockout
mice, as reported separately [26]. A large number of genes
that were downregulated in the Ppara siRNA–treated liver
proﬁles either were not downregulated or were upregulated
in the Ppara knockout liver proﬁles, and vice versa. Hence,
Ppara siRNA, delivered by tail vein, has a signiﬁcant effect on
both on- and off-target genes in vivo. The transcriptional
response to Ppara siRNA treatment provides an ideal dataset
for inferring pairwise regulatory relationship genes by local
constraint algorithm (LCA) in that the external perturbation,
or the instrumental variable, on the system can be measured.
Figure 2 summarizes the three major causality relationships
for the impact of siRNA on PPARa, PPAR downstream genes,
PPAR siRNA off-target genes, and cellular responses. The
causal models corresponding to all illustrated scenarios and
their combinations share a common regulatory relationship
between X and Y (designated as X ! Y), representing genes
and/or cellular responses affected by the perturbation
variable, W, or a hidden variable, H, which is not measurable
in the current system (Figure 2B, 2D, and 2F). Because the
mRNA levels for both the on- and off-target genes are
controlled by the siRNA, we considered the effect of Ppara
siRNA as the instrumental variable (W), which is manifested
and can be measured by the mRNA level of Ppara in response
to the siRNA treatments. Without genome-wide perturbation
induced by the off-target effect of Ppara siRNA, expression of
the genes associated with Ppara, such as gene X and gene Y, in
the Ppara siRNA–treated proﬁles should highly correlate with
expression of Ppara. Hence, it would be impossible to
determine the regulatory relationship between gene X and
gene Y. However, the off-target effects of different Ppara
siRNAs often introduce additional perturbations on X and Y
differentially, making it possible to derive the regulatory
relationship between gene X and gene Y. For example, when
two conditions—(1) the correlation between Ppara and gene Y
is disrupted by the off-target effects, but the correlation
between Ppara and gene X remains in some proﬁles, and (2)
the disruption of the correlation between Ppara and gene X is
parallel to the disruption of correlation between Ppara and
gene Y in the other proﬁles—are met simultaneously for
Ppara, gene X, and gene Y, then the observation, which
statistically satisﬁes the Ppara and Y conditional independ-
ency given X, indicates that it is more likely that X regulates Y
than that Y regulates X. Consequently, when W, an instru-
mental variable whose value is controlled by a deﬁned input
or signal, is known, the causal relationship between X and Y
can be inferred computationally [27,28]. More comprehensive
statistical tests, such as the LCA, to estimate the likelihood of
X regulating Y given an instrumental variable W over all other
possible relationships among X, Y, and any other hidden
variables, have been previously established for general data-
mining purposes [27]. Our two-step relay approach used LCA
to infer all pairwise causal relationships between a top gene
Figure 1. Effective Modification of Ppara mRNA and Its Known Target Genes by siRNA In Vivo
Ppara was monitored with three probes, Ppara 1, 2, and 3, targeting different fragments of the whole Ppara transcript. The mRNA levels of Ppara, as
detected by all three Ppara probes (A), and by its known target genes Cpt1a (B) and Acadl (C) decreased coordinately in the livers of mice treated with
Ppara siRNA1 and Ppara siRNA2. The mRNA levels of Ppara and its known target genes, Cpt1a or Acadl, were also measured in Ppara
 /  mice as a
positive control for the silencing effect of Ppara siRNA. Similar concordant regulation between Ppara and its known targets is observed in Ppara
 / mice
when compared with wild-type mice at day 1 (D1) or day 7 (D7) after vehicle treatment. The mRNA level for each mouse is indicated by a vertical bar.
doi:10.1371/journal.pcbi.0030030.g001
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Sufficiency Network for Liver Hypertrophy(X) and a bottom gene (Y) in the ﬁrst step, and a causal gene
(X) and its cellular response (Y) in the second step.
Speciﬁcally, we used LCA to identify gene pairs in which
one was conditionally independent of Ppara when the other
was conditioned on Ppara (Figure 3). When conditioned on
the identiﬁed top genes, the correlation between the bottom
gene and siRNA effect, manifested by the mRNA level of
Ppara, vanished (Figure 3A, red dots). However, when
conditioned on the bottom genes, the correlation between
Ppara and the selected top genes remained signiﬁcant (Figure
3B, red dots). Among approximately 25,000 genes proﬁled,
5,650 transcripts regulated by Ppara siRNA in at least one
mouse liver (p , 0.01 revealed by a platform error model)
were tested for potential pairwise relationships by LCA
(Table S1). A total of 22,256 gene pairs that satisﬁed all of the
six criteria speciﬁed in Materials and Methods were selected
as the top–bottom, or upstream–downstream, gene pairs (X
! Y) from the mouse expression proﬁles. These gene pairs
with inferred regulatory relationships accounted for about
0.07% of all potential pairs among the 5,650 transcripts
tested.
Deriving Genes Mediating PPARa–AILH from a Rat PPAR
Liver Minicompendium
In the second step of our approach, we inferred the causal
genes for liver hypertrophy induced by PPARa activation by
using the derived regulatory relationship within these gene
pairs. Of the 5,650 mouse transcripts tested, 2,569 had
reciprocal orthologs on the rat chip used for proﬁling the
liver responses to PPARa agonists (Table S2). A total of 4,727
gene pairs with inferred regulatory relationships were
identiﬁed among the 2,569 mouse genes with rat orthologs.
Similarly, these gene pairs represented 0.07% of all potential
pairs among the 2,569 genes. Assuming that the regulatory
relationships derived in the mouse liver hold in the rat liver,
we selected gene pairs only if there existed conditional
independency between gene X and hypertrophy given gene Y
in the PPAR minicompendium [29] and not conditional
independency between gene X and gene Y given hypertrophy
(Figure 3D–3F). Speciﬁcally, for all of the selected gene pairs,
the dependency between the top genes and liver hypertrophy
was abolished when conditioned on the bottom genes (p ,
0.01) (Figure 3D, red dots). The dependency between the top
genes and bottom genes remained when conditioned on liver
hypertrophy (Figure 3E). So did the dependency between
liver hypertrophy and the bottom genes (p , 0.01) when
conditioned on the top genes (Figure 3F). The Y genes in the
selected gene pairs were identiﬁed as the causal genes for
PPARa–AILH if they occurred in at least one gene pair. We
identiﬁed 39 transcripts as candidates most likely mediating
PPARa–AILH (p , 0.01), and 16 of these transcripts—
corresponding to 15 genes and one expression sequence tag
(EST)—were signiﬁcant at the level of p , 5 3 10
 4 (Table 1).
To check for false-positives among the derived relation-
ships after multiple tests, we conducted a Monte Carlo
simulation. The false-positive rate was estimated based on
1,000 simulations testing all 4,727 gene pairs. The chance of
false discovery for the inferred causal genes mediating the
PPARa–AILH was 0.002.
To validate our assumption that the regulatory relationship
between gene pairs inferred in the mouse was retained in the
rat, the conditional independencies between PPARa activity
(measured by PPARa direct targets) and bottom genes given
top genes for all 16 identiﬁed transcripts were examined in
Figure 2. Schematic of the LCA That Determines Genes Mediating Certain Cellular Responses from Expression Profiles after Perturbation by siRNA
The three major scenarios for the effect of siRNA on gene expression and biological response are illustrated in (A): the direct target or the on-target
gene for siRNA and/or its downstream regulated genes resulting in a cellular response; (C): the off-target genes and their downstream regulated genes
causing the cellular response; and (E): the cellular effect of an siRNA toward on-target and/or off-target genes and their downstream regulated genes
leading to the cellular response. The corresponding causal models among the instrumental variable W, the top gene X, and the bottom gene or
response Y for these scenarios are shown in (B,D,F). The hidden variable, H, is not measurable by expression profiles. The flow chart for two-step relay is
illustrated in (G).
doi:10.1371/journal.pcbi.0030030.g002
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Sufficiency Network for Liver Hypertrophythe rat liver PPAR minicompendium. Nine (56%) of the 16
transcripts satisﬁed the statistical tests. The remaining seven
transcripts may have been excluded as a consequence of the
different criteria used for measuring PPARa perturbation
between the mouse and rat studies. For example, in the
mouse study, PPARa activity was measured directly by the
mRNA level in siRNA proﬁles, whereas in the rat study, it was
measured indirectly by the mRNA levels of the PPARa target
genes. Nevertheless, 11 of the 15 identiﬁed genes have
comprehensive functional annotations, and eight of these
11 genes (73%) have been reported either to be associated
with or to cause liver hypertrophy or hepatomegaly [30–32].
Verifying the Inferred PPARa–AILH Causal Genes by Their
Capability to Predict Non-PPARa–Induced Liver
Hypertrophy
We assumed that liver hypertrophy is mediated by a
common essential molecular mechanism, even if it can be
induced by differing top signals. Therefore, there should be a
set of core genes that are essential for liver hypertrophy
regardless of whether the hypertrophy results from PPARa
activation or other conditions. If some of the 16 identiﬁed
transcripts are essential for liver hypertrophy, we would
expect them to have predictive power for compound-induced
liver hypertrophy regardless of the compounds’ mode of
action; otherwise, the derived causal effect of these 16
transcripts for liver hypertrophy cannot be sustained. To
test this hypothesis, we proﬁled 211 rats that were treated
with 30 non-PPAR compounds and determined their liver/
body weight ratio, as an indicator of liver hypertrophy (Table
S3). A logistic regression-based classiﬁer for liver hypertrophy
was built based on nine of the 16 identiﬁed causal transcripts
from the 211 proﬁles as the training set. The optimal number
of transcripts among the 16 inferred transcripts was
determined by their contribution to the ﬁt of the model for
predicting liver hypertrophy. The accuracy of the model was
measured by the root-mean-squared error estimated by leave-
one-out validation. Nine transcripts were selected to build
the best-ﬁtted model with the least difference between the
measured and predicted ratios of liver to body weight in the
training set. The built model predicted liver hypertrophy in
the training set with 96% sensitivity and 80% speciﬁcity
(Figure 4B, Table 2).
To further validate this model, we assessed its performance
in an independent testing dataset. This dataset consisted of
the nine genes and liver/body weight ratios from another set
of 107 rat liver proﬁles obtained in response to treatment
with 17 non-PPARa compounds (Table S4). These compounds
have mechanisms of action or targets that differ from those of
the 30 non-PPARa compounds used in the training set. The
nine-gene model built in the training set achieved 84%
sensitivity and 76% speciﬁcity in predicting liver hyper-
trophy in the independent testing set (Figure 4C and Table 3).
This ﬁnding suggests that we can predict liver hypertrophy
based on this model with an acceptable level of conﬁdence
regardless of the type of top signals that induce the liver
hypertrophy.
Of note, the selection of the 16 candidate transcripts on
which the model was built was not dependent on either of the
datasets used for training and testing. To determine if the
Figure 3. Identification of the Top and Bottom Gene Pairs and the Causal Genes for PPARa–AILH by the Two-Step Relay Approach
Conditional independency between the instrumental variable (Ppara) and the bottom gene given the top gene in selected gene pairs (A–C) is
illustrated. When conditioned on the identified top genes, indicated in red (A), the correlation between siRNA effect, manifested by Ppara mRNA level
and the bottom genes, vanishes. However, when conditioned on the bottom genes, indicated in red (B), the correlation between Ppara and the selected
top genes remains significant. Similarly, the dependency between the top genes and liver hypertrophy is abolished when conditioned on the bottom
genes (p , 0.01), indicated by red dots in (D). The dependency between the top genes and bottom genes remains when conditioned on liver
hypertrophy (E), as does the dependency between liver hypertrophy and the bottom genes (p , 0.01) when conditioned on the top genes, indicated by
red dots (F). To assess the false-positive rate among the derived relationships after multiple tests, Monte Carlo simulation was done. The estimated false-
positive rate for the 15 genes and one EST inferred to mediate PPARa–AILH after testing all of the top and bottom gene pairs is 0.002.
doi:10.1371/journal.pcbi.0030030.g003
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Sufficiency Network for Liver Hypertrophycausal information is necessary for such performance in
predicting liver hypertrophy, we examined the possibility of
achieving an equivalent level of accuracy in predicting liver
hypertrophy based on genes selected solely by their associ-
ation or correlation with the liver/body weight ratio in the
PPAR minicompendium. Based on correlation with liver/body
weight ratio, we identiﬁed 757 genes that had a value equal to
or greater than that of the 16 inferred causal transcripts in
the PPAR minicompendium. The identiﬁed genes were used
as a candidate pool to build a correlation-based model. In
total, we built 10,000 models based on 10,000 sets of 16 genes
randomly selected from the candidate pool. Using the area
under the curve (AUC) from a receiver operating character-
istic (ROC) plot (a common indicator for model perform-
ance), we estimated the distribution of the performance for
these 10,000 models. This in silico simulation revealed that
none of the models in the training set, and only 37 of the
models in the testing set, achieved a level of performance at
Table 1. Fifteen Genes Inferred as Mediating PPARA–AILH and Their Functional Annotations
Gene Symbol
(Entrez Gene ID)
Gene Name Alternate
Symbols
Function
Acadm
a,b (34) Acetyl-coenzyme A dehydrogenase,
medium chain
MCAD Involved in fatty acid beta-oxidation and likely energy path-
ways; human ACADM mutation is associated with medium-
chain acyl-CoA dehydrogenase deficiency characterized by fast-
ing intolerance and hypoglycemic coma
3110048E14Rik
b
(73225)
RIKEN cDNA 3110048E14 gene C230014M12Rik Protein of unknown function, has very strong similarity to un-
characterized human FLJ20635
Pitrm1
b (69617) Pitrilysin metalloprotease 1 MP1; Ntup1;
mKIAA1104;
2310012C15Rik
Protein with strong similarity to metalloprotease 1 (human
PITRM1), which is a metalloendoprotease that may play a role
in general cellular regulation, contains two peptidase M16 inac-
tive domains
Pck1
a (5105) Phosphoenolpyruvate carboxykinase 1,
cytosolic
PEPCK; Pck-1 Decarboxylates oxaloacetate to form phosphoenolpyruvate in
the gluconeogenesis pathway, regulates glyceroneogenesis; hu-
man PCK1 may be a candidate for early-onset non–insulin-de-
pendent diabetes mellitus
9430083G14Rik
(68817)
RIKEN cDNA 9430083G14 gene — Protein of unknown function, has strong similarity to uncharac-
terized human UNQ8193
Golga4 (2803) Golgi autoantigen, golgin
subfamily a, 4
Olp-1; olp-1 Contains a novel Golgi-targeting GRIP domain, interacts with
small GTPase Rab6, and may be involved in membrane tether-
ing; corresponding human GOLGA4 is an autoantigen in pa-
tients with Sjogren syndrome
Cdc2a
a,b (12534) Cell division cycle 2 homolog A
(Schizosaccharomyces pombe)
Cdc2; p34 Cyclin-dependent protein kinase that has a key role in regulat-
ing entry into mitosis and the G2 to M phase transition, pro-
motes cell proliferation, involved in meiosis; human CDC2 is im-
plicated in Alzheimer disease
Pex19
b,c (5824) Peroxisome biogenesis factor 19 Pxf Farnesylated peroxisomal protein, interacts in the cell cyto-
plasm with p19ARF, which then inhibits p53 (Tp53) activation,
regulates cell proliferation, and may function in cell cycle con-
trol; human PXF is associated with Zellweger syndrome
2010309E21Rik
(66488)
RIKEN cDNA 2010309E21 gene — Member of the DUF842 domain of unknown function family,
has strong similarity to uncharacterized human FLJ14668
Lpin2 (9663) Lipin 2 2610511G02Rik Member of a family of proteins related to lipin 1 (Lipn1), a pu-
tative nuclear protein that contains an N-terminal lipin (NLIP)
domain and a C-terminal lipin (CLIP) domain
Scd1
a (20249) Stearoyl-coenzyme A desaturase 1
(Delta(9) acyl-CoA desaturase)
ab; SCD; Scd-1 Catalyzes the synthesis of the monounsaturated fatty acids ole-
ate and palmitoleate; human SCD is upregulated in colonic car-
cinomas, esophageal carcinomas, and breast cancer
Nr1i3
a (9970) Nuclear receptor subfamily 1, group I,
member 3
CAR; CAR1; CAR2;
MB67; mCAR;
Care2; ESTM32
A member of the nuclear hormone receptor superfamily, binds
DNA as a heterodimer with the retinoid-X receptor, and acti-
vates gene transcription; involved in drug and xenobiotic meta-
bolism
2700017I06Rik
b
(209630)
RIKEN cDNA 2700017I06 gene mKIAA1294;
5330420J21;
C230040M21Rik
Protein with strong similarity to grp1 binding protein Grsp1
(mouse 6030440G05Rik), which is a putative scaffolding protein
involved in the insulin response, member of the FERM domain
(Band 4.1 family) family
Apoa4
a,b (337) Apolipoprotein A-IV Apoa-4 Involved in cholesterol transport, lipid homeostasis, and regula-
tion of feeding behavior; human APOA4 is associated with car-
diovascular pathology in non–insulin-dependent diabetes melli-
tus and with amyloid deposits in senile systemic amyloidosis
Acac
a,b (31) Acetyl-coenzyme A carboxylase alpha Acc1 Necessary for nutrient-induced insulin secretion, upregulated
by exercise training
aThe inferred causal effect on liver hypertrophy is supported by phenotypes observed in mice after gene-targeting or antisense oligonucleotide treatment [31,33,34,36–40].
bGenes were selected for the liver hypertrophy classifier.
cReannotated as Trial 1 after the sequence was aligned with the current version of chip annotation.
doi:10.1371/journal.pcbi.0030030.t001
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Sufficiency Network for Liver Hypertrophyleast equal to that of the model based on inferred causal
genes in predicting liver hypertrophy. The probability of
building a model with at least the same level of performance
as that built from the inferred causal transcripts was
exceedingly small for both the training set (p , 0.001, Figure
4E) and the testing set (p , 0.005, Figure 4F). Hence,
correlation alone is insufﬁcient for extrapolating the capa-
bility of the 16 inferred PPARa–AILH causal transcripts to
predict liver hypertrophy induced by non-PPAR compounds.
The predictive power of the inferred PPARa–-AILH causal
transcripts for non-PPAR–induced liver hypertrophy sup-
ports the assumption that essential biological components for
liver hypertrophy exist. The inferred causality relationship
between the 16 transcripts and liver hypertrophy is essential
for the extrapolation of this prediction model.
Inferring the Sufficiency Order among the Derived Causal
Genes for Liver Hypertrophy
Finally, we determined the sufﬁciency order for mediating
PPARa–AILH among the 16 transcripts by exhaustive
pairwise conditional independent (CI) tests (Figure 5 and
Figure S1). There were 15 genes with known or predicted
proteins among the 16 derived causal transcripts. CI tests
identiﬁed nine of these genes as the most sufﬁcient ones in
inducing liver hypertrophy. For instance, as revealed by
conditional dependency between Pck1 and PPARa–AILH
given the constraint of the inferred causal relationship
between Acadm and PPARa–AILH, Pck1 is more sufﬁcient
than Acadm in mediating PPARa–AILH (Figure S1A).
This order is also in agreement with observations in Pck1
null mice and Acadm null mice. Acadm, also called medium-
chain acyl-CoA dehydrogenase (MCAD), encodes an essential
enzyme for fatty acid oxidation. MCAD deﬁciency in mice or
humans can cause liver hypertrophy and hepatic steatosis
[32,33]. Meanwhile, Pck1, also known as phosphoenolpyruvate
carboxykinase (PEPCK), encodes a rate-limiting enzyme for
gluconeogenesis. PCK1 deﬁciency is lethal in both mice and
humans [34,35]. However, liver hypertrophy and steatosis
have been observed in liver-speciﬁc PCK1-deﬁcient mice [34];
after 14 hours of fasting, such mice have a 71% increase in
liver weight along with signiﬁcant hepatic lipid accumulation.
Furthermore, although these mice have elevated expression
of MCAD, this does not reverse the gain in liver weight
induced by PCK1 deﬁciency. Similarly, an exhaustive search
over all potential gene pairs between Pck1 and the other
inferred causal genes for PPARa–AILH revealed that Pck1 is
more sufﬁcient in mediating liver hypertrophy than are
Pex19, Car, Pitrm1, and 3110048E14Rik.
Based on our knowledge or lack of knowledge about their
functions, the nine genes derived to be most sufﬁcient in
mediating liver hypertrophy represent four groups: a fatty
acid, lipid genesis, or energy metabolism group, including
Pck1, Apoa4, Scd1, Acac, and Lpin2; a cell proliferation group,
Cdc2a, also known as cdk1; a Golgi group, Golga4; and a group
with unknown function, 2010309E21Rik and 9430083G14Rik.
Five of these genes, Pck1, Apoa4, Scd1, Acac and Cdc2a, have
been reported to be modiﬁed by gene-targeting or antisense
oligonucleotide treatment, and in all ﬁve cases the resulting
phenotypic alterations in the liver are consistent with the
gene’s inferred causal effect on liver hypertrophy as
determined by our method [31,33,34,36–40].
In a ﬁnal analysis, we examined potential reduction of
statistical power associated with multiple tests for the genes
with the maximal number of downstream genes mediating
PPARa–AILH. For the nine genes that exhibited the highest
sufﬁciency in mediating liver hypertrophy, the estimated
probability that an additional causal gene from the rest of the
16 transcripts could be more sufﬁcient for the hypertrophy
was p ¼ 0.07.
Table 2. Estimated Optimal Performance of the Logistic
Regression Model in the Training Set (n ¼ 211 Profiles)
Training Set Predicted
Normal
Predicted Liver
Hypertrophy
Expected Normal 147 37
Expected Liver Hypertrophy 1 26
doi:10.1371/journal.pcbi.0030030.t002
Table 3. Estimated Performance of the Logistic Regression
Model in the Independent Testing Set (n ¼ 107 Profiles)
Testing Set Predicted
Normal
Predicted Liver
Hypertrophy
Expected Normal 62 12
Expected Liver Hypertrophy 8 25
doi:10.1371/journal.pcbi.0030030.t003
Figure 4. Predictability of Liver Hypertrophy Induced by Non-PPARa Compounds from Inferred PPARa–AILH Causal Genes
Nine selected transcripts for the logistic regression model from the 16 inferred causal genes were coordinately regulated in the training set (A). A total
of 211 expression profiles for the nine measured transcripts were aligned with liver hypertrophy, defined by the liver/body weight ratio (B) in
corresponding rats (color bar: 0.3:0.3 at log10 scale). The expected normal liver and liver hypertrophy (LH), based on measured liver/body weight ratio
in the training set, are indicated by blue dots and diamonds, respectively, while the predicted normal liver and LH derived from the established model
are indicated by red dots and diamonds, respectively (B). Based on the logistic regression model built from the training set, the pathological condition
of the liver in the independent testing set (normal or hypertrophy) was predicted (D). The expected normal liver and LH based on measured liver/body
weight ratio in the testing set are illustrated by blue dots and diamonds, respectively. The predicted normal liver and LH derived from the established
model from the training set are indicated by red dots and diamonds, respectively. Distinctive patterns of the selected biomarkers are evident between
the normal and hypertrophic livers [(A,C); color bar:  0.3:0.3 at log10 scale]. The probability of obtaining such a set of predictive biomarkers from the
genes correlated with the liver/body weight ratio in the PPAR minicompendium was significantly small in both the training dataset [(E), p , 0.001] and
the testing dataset [(F), p , 0.005]. The AUCs for the ROC of the built model based on causal transcripts are indicated by the blue and red bars for the
training and testing dataset, respectively, among the distribution of AUCs for 10,000 trials of 16 genes randomly selected from 757 genes correlated
with the endpoint in the minicompendium (E,F).
doi:10.1371/journal.pcbi.0030030.g004
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Overall, our genome-scale approach provides a powerful
tool for unveiling components of potential pathways and the
order of their sufﬁciency relationships in mediating a drug-
induced toxicity. In selecting an example, we applied our
approach to identify the key molecular components and their
sufﬁciency order in PPARa–AILH. The proposed 15 causal
genes not only reveal the molecular mechanism of this
phenomenon, which is in agreement with that shown in
previous studies, but also suggest potential unknown common
mechanisms underlying liver hypertrophy. The inferred
causality hypotheses orientated to a certain type of toxicity,
in this case, liver hypertrophy, are essential in discovering the
potential mechanism of drug-induced toxicity.
Facilitating De Novo Discovery of Pathways in Rodents
with RNAi Treatment Targeting a Single Gene
Computational approaches for de novo discovery of
regulatory networks have been previously reported [14–20].
A few have attempted to associate the derived network with
speciﬁc biological outcomes [18,22–24]. Nevertheless, appli-
cation of these approaches in rodents is impeded by their
requirement for a large number of targeted genetic pertur-
bations or prior knowledge of the pathway. Our approach
overcomes such hindrance by taking advantage of the siRNA
off-target effects as additional genome-wide perturbations.
Using the mRNA level of an siRNA-targeted gene, in the
current case, Ppara, as the instrumental variable, in the
siRNA-treated expression proﬁles, we were able to infer
pairwise regulatory relationships by a simple but well-
established LCA originally developed for data mining [27].
Instead of approximating a global regulatory structure, we
focused on the sufﬁciency order among the causal genes
identiﬁed by the two-step relay approach. Taking advantage
of the derived causal structure from the causal gene to the
liver hypertrophy as local constraints, the searching space for
the 16 derived transcripts was reduced from O(2
g)t oO(g
2),
where g is the number of derived causal genes. In our case, the
searching space was reduced by 272-fold. This dramatic
reduction enabled us to exhaustively search for the sufﬁ-
ciency network, which was, otherwise, computationally
expensive or simply infeasible. In contrast, most of the
previously reported approaches require Monte Carlo Markov
chain or other sampling techniques to search for a local
optimal network as an approximation of the global optimal
structure.
Moreover, the derived pairwise regulatory relationships
from siRNA expression proﬁles can also beneﬁt most of the
currently used computational approaches for pathway de
novo discovery. For example, application of these relation-
ships as local constraints in Monte Carlo Markov chain–based
Bayesian methods will reduce the searching space and
consequently improve the chance that any resulting local
optimal structure is the real global solution.
The two-step relay strategy offers unprecedented ﬂexibil-
ity, although the assumption of retained pairwise relation-
ships among the gene pairs derived from the ﬁrst step is
essential and needs to be experimentally examined. Because
the derived regulatory relationship between the top (up-
stream) gene and the bottom (downstream) gene reﬂects a
transcriptional regulatory relationship within a gene pair,
these relationships are independent from the instrumental
signal, in our case, Ppara. As a result, such regulatory
relationships can be used to infer causal genes for any
phenotypic changes induced by compounds or other types of
perturbation. This portability of the inferred regulatory
relationship within gene pairs is extremely helpful for
toxicogenomics study because the majority of toxicity studies,
including gene expression proﬁle studies, are performed in
rats, whereas knockout or RNAi silencing is most commonly
undertaken in mice.
In this work, we used perturbation introduced by siRNA
targeting one gene. It is conceivable that the coverage and
reliability of pairwise relationship across the genome can be
further improved if multiple siRNAs targeting different genes
are applied. Meanwhile, other strategies can be applied to
Figure 5. The Sufficiency Order Network of the 15 Causal Genes Mediating PPARa–AILH, as Determined by CI Tests against Liver Hypertrophy
doi:10.1371/journal.pcbi.0030030.g005
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relationship. For example, genetic engineering of top genes
in C. elegans or Drosophila can be used to verify the regulatory
effect of top genes on bottom genes, the key assumption of
our method. Monitoring the temporal relationship between
the expression regulations of these inferred causal genes and
the phenotypic outcomes in liver will enable further
validation of the inferred causal network in rodents as well.
Consequently, a genome-wide phenotype-oriented network
can be inferred and tested in a relatively high throughput
fashion.
Exploring Differences among Classification, Causality, and
Extrapolation
Classiﬁcation does not prove a causal relationship. Yet,
only a causal relationship will enable extrapolation of an
established model into prediction. Hence, capability of
extrapolation can be used as a test of the derived causal
relationship. Many classiﬁers or gene sets, established by
vigorous machine learning procedures, have been reported to
describe the extent of drug-induced toxicity or the outcome
of cancer with reasonable accuracy. However, they do not
allow us to distinguish whether these identiﬁed gene sets have
a functionally important role in mediating those observed
outcomes or are merely indicators for the underlying
propensity of those outcomes. The performance of such
types of classiﬁers for predicting drug-induced toxicity will be
affected by the diversity of compounds used in the training
set and testing set. When toxicity has to be predicted for
compounds affecting targets different from the targets
affected by compounds in the training set, the performance
of a classiﬁer not based on causality information will
deteriorate dramatically. In other words, a classiﬁer that is
not based on causality will rarely have the capability of
extrapolation. Our comparison between classiﬁers based on
genes selected by inferred causality and by correlation alone
demonstrates that causality information is necessary for
compound-independent extrapolation in toxicity prediction
(Figure 4). The performance of classiﬁers built on genes
selected from the 757 genes correlated with liver/body weight
ratio in the PPAR minicompendium became substantially
inferior when these classiﬁers were used to predict liver
hypertrophy induced by non-PPAR compounds. Our simu-
lation indicates that classiﬁers based on correlated genes
alone are unlikely to successfully predict or extrapolate drug-
induced toxicity independently from the mode of action of
compounds used in training set (p , 0.005). In contrast, the
classiﬁer we built based on inferred causal genes can predict
liver hypertrophy independent from compounds’ modes of
action in the original training set. The capability of
extrapolating a model that was initially built on PPAR
compounds into predicting liver hypertrophy regardless of
a compound’s primary targets has not been demonstrated in
any previous reports and has not been examined for
classiﬁers based on association markers.
The legitimacy of using the capability of extrapolation as
an analytic validation approach for the inferred causal genes
is further supported by experimental evidence for the
inferred 16 causal transcripts in in vivo models
[31,33,34,36–40]. More than 85% (six of seven) of the inferred
causal genes that have been genetically modiﬁed or speciﬁ-
cally targeted in in vivo models are associated with
phenotypic abnormalities in the liver that are in agreement
with the role of these genes in mediating liver hypertrophy
(Table 1). Five of them are among the genes with highest
sufﬁciency in causing liver hypertrophy. In contrast, the rate
of discovering functionally related genes among the top-
ranked markers in an association-based classiﬁer is quite low.
For instance, Furey and colleagues detected only three genes
that are cancer-related among the top ten most discrim-
inative genes or ESTs for classifying ovarian cancer [41]. The
rate for cancer-related genes or ESTs may be underestimated
because they exclude noncoding sequences, which have been
recently shown to play an important role in tumorigenesis.
Nonetheless, the lack of evidence for the capability of
extrapolating their association-based model into predicting
outcomes of other solid tumors is in agreement with the
contention that causality is a prerequisite for the capability of
extrapolation in predicting outcomes.
Evaluating Statistical Power and Assumptions in the Two-
Step Relay Approach
Although we have made every effort to analytically validate
the derived results of causal relation in general, several
factors may affect our results. First, the assumption that the
derived pairwise regulatory relationship between a top gene
and a bottom gene is valid in both mouse and rat liver may
not hold all the time. To gain conﬁdence in this assumption,
we examined the statistical conditional independence be-
tween PPARa activity, measured by direct targets of PPARa,
and bottom genes given top genes for all 16 identiﬁed
transcripts using the PPAR minicompendium. We found that
nine of the 16 transcripts were more likely to retain the same
top–bottom relationship as derived from the siRNA proﬁles.
Of note, the original 16 gene pairs were established by
treating the mRNA level of PPARa as a direct measurement
of perturbation on Ppara in siRNA-treated proﬁles, whereas
the nine gene pairs were reestablished by treating mRNA
levels of Cpt1a and other genes known to be PPARa
downstream genes as an indirect measurement of perturba-
tions on Ppara in the PPAR minicompendium. Second,
statistical power could be reduced with multiple tests. For
example, false-positives may occur among the inferred causal
genes for PPARa–AILH after testing all the 4,727 gene pairs.
The estimated false-positive rate for the 16 identiﬁed tran-
scripts was 0.002. Third, a measurement error associated with
expression proﬁles could affect the sensitivity and speciﬁcity
of our analysis. To account for this error, we used error-
weighted mean logarithmic ratios in our analysis. Cross-
validation from different platforms or independent experi-
ments will help further address this issue.
Uncovering Distinguishing Molecular Mechanisms
Underlying PPARa–AILH
The ﬁve identiﬁed most sufﬁcient causal genes for PPARa–
AILH suggest that three major molecular mechanisms
underlie the increases in liver weight mediated by this
receptor: increased cell proliferation, altered fatty acid or
l i p i dm e t a b o l i s m ,a n da f f e c t e df u n c t i o no ft h eG o l g i
apparatus. In agreement with observations in humanized
PPARa mice treated by PPARa ligand Wy-14643, our results
suggest that Cdc2a (cdk1), a cell cycle control gene, may
increase liver weight by enhancing cell proliferation. As
shown by Gonzalez and colleagues, replacing murine PPARa
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proliferating cells and inhibits the level of cdk1 in the
presence of Wy-14643 [37]. Although they clearly demon-
strated the rodent speciﬁcity for the effect of PPARa
activation in cell proliferation and tumorigenesis, the down-
stream genes mediating the proliferation effects of Wy-14643
remained largely unknown [37,38]. Our study provides a
testable hypothesis for the role of Cdc2a or cdk1 in mediating
the rodent-speciﬁc tumorigenic effect of PPARa activation. A
cross between humanized PPARa mice and liver-speciﬁc
Cdc2a knockout mice will be a perfect model to evaluate the
hypothesized contribution of Cdc2a to PPARa activation–
induced cell proliferation and tumorigenesis.
The contribution of fatty acid or lipid metabolism to
PPARa–AILH, suggested by our observations, is also sup-
ported by phenotypic changes reported in several genetically
modiﬁed mouse models, including the mice with humanized
PPARa. For instance, both Acadm, a gene critical for fatty acid
metabolism, and the extent of liver hypertrophy, measured by
either the absolute liver weight or the liver/body weight ratio,
are increased by PPARa ligand Wy-14643 in mice with or
without humanized PPARa despite the fact that cell pro-
liferation is dramatically reduced with the humanized
receptor PPARa [37,38]. Furthermore, for inferred causal
genes downregulated by PPARa ligands, such as Pck1 and
Apoa4, knocking out these genes results in signiﬁcant
increases in liver weight and liver/body weight ratio or in
fatty liver [34,39]. The increased liver weight or size resulting
from deﬁcient mutations of these two genes, and the fact that
PPARa activation reduces their expression, supports their
inferred role in liver hypertrophy. Additional evidence comes
from the response to the high-fat diet, the endogenous ligand
for PPARa, in mice treated with an antisense oligonucleotide
for Acac1 and Scd1 [36,40]. As the key regulators for fatty acid
oxidation and fat synthesis in the liver, Acac1 and Scd1 are
upregulated by PPARa activation as well as by a high-fat diet.
Increased expression of these genes results in increases in
liver size or weight by lipid accumulation in hepatocytes.
Antisense oligonucleotide inhibitors of Acac1 and Acac2
totally reverse this induced lipid accumulation, suggesting
that Acac1 mediates the effect of PPARa activation on lipid
accumulation in liver [40]. Similar results have been reported
in mice treated with an antisense oligonucleotide inhibitor of
Scd1 [36]. Injection of 15 mg/kg of this oligonucleotide twice a
week signiﬁcantly reduced the lipid accumulation in the liver
induced by a high-fat diet. Taken together, these reported
observations are not only in concert with our inferred role of
fatty acid metabolism and lipid synthesis in mediating
PPARa–AILH, but may also reveal a potential key patho-
logical change, lipid accumulation, linking liver hypertrophy
with fatty liver.
The role of Golga4 in mediating PPARa–AILH remains
unknown because functional studies of this gene are lacking.
However, the essential role of Golgi trafﬁc in regulating the
activation of sterol regulatory element–binding protein
(SREBP), another key regulator of lipid metabolism, points
in the same direction.
Distinguishing the proliferation component from the fatty
acid and lipid metabolism component for liver hypertrophy
is important for drug development. For example, compounds
are being developed to target Pck1 as novel therapeutic agents
for type II diabetes or obesity. Distinguishing the two
components enables us not only to predict the potential
effect on liver weight by compounds directly targeting Pck1
(Pepck), a potential therapeutic target regulated by PPARa
and the rate-limiting enzyme for gluconeogenesis, but also to
monitor any cellular proliferation associated with increased
liver weight.
Revealing Common Essential Molecular Machinery That
Mediates Liver Hypertrophy Shared by a Variety of
Compounds with Different Mechanisms of Action
The causal sufﬁciency order among the 15 derived genes
suggests that liver hypertrophy induced by compounds with
drastically different mechanisms of actions may be mediated
by common molecular components. For example, we found
that Car, another nuclear receptor whose activation is also
known to cause liver hypertrophy [31], was more sufﬁcient
than Pex19, ag e n er e q u i r e df o rt h es y n t h e s i so ft h e
peroxisome membrane, in mediating PPARa–AILH. To our
knowledge, the effect of PPARa ligands on the liver in mice
with a Car-deﬁcient mutation has never been reported;
however, liver hypertrophy induced by PPARa activation
and by Car activation might share the same mechanism, given
the extensive crosstalk between PPARa and Car ligands and
their very similar effects on some of the genes regulating fatty
acid or lipid metabolism. Finally, the capability to extrapolate
a model built on causal genes for PPARa–AILH to predict
liver hypertrophy induced by a set of non-PPAR compounds
with different mechanisms of action supports the existence of
common essential molecular machinery that mediates liver
hypertrophy independent of upstream signals.
In conclusion, our approach enables systematic inference
of testable hypotheses about potential molecular mechanisms
underlying drug-induced toxicity. The validity of any inferred
hypotheses will still be subject to experimental veriﬁcation.
Nonetheless, the derived causal sufﬁciency order provides a
way to prioritize all these hypotheses, which otherwise cannot
be tested exhaustively across the prohibitive number of
potential interactions and combinations among the genes
associated with drug-induced effects.
Materials and Methods
Ppara siRNA treatment and expression proﬁles in the mouse. Two
different siRNAs targeting Ppara and two control siRNAs targeting
secreted alkaline phosphatase (SEAP) and GL3 were delivered to the
mouse liver by hydrodynamic tail vein injection [25]. Four animals
per group were treated 48 hours before livers were collected. RNAs
were extracted and proﬁled on a custom-designed mouse oligonu-
cleotide microarray with approximately 25,000 genes according to a
published procedure [29]. In total, the Ppara siRNA mouse expression
proﬁles included eight proﬁles for the Ppara siRNAs targeted to two
different fragments of the Ppara mRNA sequence, four proﬁles for
the SEAP control siRNA, four proﬁles for the GL3 control siRNA, and
eight proﬁles for a vehicle control (Ringer solution).
Liver PPAR minicompendium and liver responsive datasets in the
rat. In brief, the PPAR minicompendium used in this study consists of
expression proﬁles of livers from 147 rats treated with activators of
PPARs and other nuclear receptors, including the PPARa agonists
fenoﬁbrate (400 mg/kg per day; Sigma-Aldrich, http://www.
sigmaaldrich.com) and Wy-14643 (100 mg/kg per day; ChemSyn
Sciences, http://www.chemsyn.com), the PPARc agonist rosiglitazone
(100 mg/kg per day), the pan-PPAR agonist bezaﬁbrate (250 mg/kg per
day; Sigma-Aldrich), and the retinoic acid receptor agonist all-trans
retinoic acid (25 mg/kg per day; Sigma-Aldrich). Female Sprague
Dawley rats (Charles River Laboratory, http://www.criver.com) 7–8 wk
of age were dosed daily for 2, 3, 4, 5, and 6 days by oral gavage. Six
hours after the last dose, animals were euthanized by isoﬂurane
inhalation followed by blood collection from the vena cava and
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animals, and the ratio of liver to body weight was used as the index for
liver hypertrophy. RNAs were extracted from liver and proﬁled on a
custom-designed rat oligonucleotide microarray with approximately
25,000 genes according to a published protocol [29]. The error-
weighted ratios for the 2,569 transcripts used in our study are
summarized in Table S2. A similar study was conducted using 318 liver
samples from rats treated with 47 compounds whose primary targets
were not PPARs, hereafter referred to as non-PPAR compounds. Data
used in our analyses are summarized in Table S3. All the animals used
in these experiments were handled in laboratories accredited by the
Association for Assessment and Accreditation of Laboratory Animal
Care International. The animal studies were conducted with Institu-
tional Animal Care and Use Committee approval. A comprehensive
summary of related data and analyses for this PPAR rat liver
minicompendium were reported separately [29].
Local constraint algorithm analysis for inferring causal regulatory
relationships from siRNA-treated expression proﬁles. The three
causal models corresponding to the major scenarios for the impact of
siRNA on other genes and cellular responses (Figure 2) share a
common regulatory relationship between X and Y (denoted as X !
Y). Cooper [27] and Spirtes and colleagues [28] have demonstrated
that when W is an instrumental variable, or when W is not caused by
any measurable variables, such as X and Y, the causal relationship
between X and Y can be inferred by a constraint-based causal
discovery method. Speciﬁcally, when six dependent and independent
constraints among W, X, and Y hold—(1) D(W, X), representing
dependence between W and X, (2) D(X, Y), (3) D(W, Y), (4) D(W, X
given Y), representing dependence between W and X when condi-
tional on Y, (5) D (X, Y given W), and (6) I (W, Y given X), representing
independence between W and Y when conditional on X—it was
sufﬁcient to identify the causal relationship X ! Y from 96 possible
regulatory models among the triplet W, X, and Y elicited by Cooper
[27]. Because the mRNA levels of siRNAs’ on- and off-target genes are
presumably controlled by the siRNA, the mRNA level of the siRNA-
targeted genes could be considered a good measure for the on-target
e f f e c to ft h es i R N A .T h e r e f o r e ,t h es i R N Ac a ns e r v ea st h e
instrumental variable (W). Furthermore, it was assumed that the
relationship between X and Y was not confounded by W or any
hidden process in the possible scenarios for the impact of the siRNA.
Therefore, those pairwise causal relationships between a top gene (X)
and a bottom gene (Y), or a causal gene (X) and its cellular response
(Y), affected by siRNA targeting a single gene can be inferred by LCA
from expression proﬁles on the genome scale [27].
A two-step relay method for inferring genes mediating PPARa–
AILH from the PPAR minicompendium. Genes mediating PPARa–
AILH were inferred by a two-step relay method as illustrated in
Figure 2G. In the ﬁrst step, the pairwise causal relationship (X ! Y)
between genes was inferred by LCA from the expression proﬁles
obtained in response to Ppara siRNA treatment. In the second step,
the derived relationship X ! Y was relayed to identify the local causal
structure among the top gene (X), the bottom gene (Y), and the
phenotypic response (R), liver hypertrophy. The top gene (X) was
then considered as the instrumental variable W, the bottom gene (Y)
was considered as X, and the response (liver hypertrophy) was
considered as Y in our causal model (Figure 2). Similarly, as speciﬁed
by Cooper’s LCA, when the six previously deﬁned constraints hold, it
is sufﬁcient to infer the causal relationship Y ! R, with which the
bottom gene Y causes R (i.e., liver hypertrophy), in the second step
from the PPAR minicompendium. The key assumption that permits
the relaying is that the regulatory relationship, X ! Y, within the
gene pairs derived from the mouse liver expression proﬁles is valid in
the rat liver expression proﬁles.
Constraint-based method for determining a sufﬁciency order
among causal genes. The sufﬁciency order among causal genes (Y,
Y9,Y 99, ...) was determined by a series of CI tests between two causal
genes and the cellular response. Speciﬁcally, when two criteria are
met—(1) a causal gene Y and a cellular response R are independent
given another causal gene Y9, and (2) gene Y9 is not independent with
cellular responses conditioning on gene Y—gene Y9 was considered to
be more sufﬁcient than gene Y in causing the cellular response R.B y
exhaustively examining all pairwise relationships among causal genes
(Y, Y9,Y 99, ...), the sufﬁciency order network among all identiﬁed key
genes can be established.
Supporting Information
Figure S1. Determination of the Sufﬁciency Order among Pck1, Apoa4,
and Acadm in Mediating PPARa–AILH by Conditional Dependency
Testing
Although regulation of both Pck1 and Acadm is necessary for PPARa–
AILH, these genes are not equally sufﬁcient to mediate liver
hypertrophy. As indicated by the partial correlation coefﬁcient
between Acadm and the liver/body weight ratio when conditioned on
Pck1, Acadm is likely to be conditionally independent from liver
hypertrophy given Pck1 [(A), left, where the correlation drops to 0.1].
However, when conditioned on Acadm, the correlation coefﬁcient
between Pck1 and the liver/body weight ratio remains at a level of 0.36
((A), right). This difference suggests that Pck1 is more sufﬁcient than
Acadm in mediating PPARa–AILH. The correlation coefﬁcient
between Apoa4 and liver hypertrophy given Acadm is not signiﬁcantly
changed, implying that Apoa4 is more sufﬁcient than Acadm in
mediating PPARa–AILH [(B), right].
Found at doi:10.1371/journal.pcbi.0030030.sg001 (679 KB PDF).
Table S1. PPARa siRNA–Treated Mouse Liver Dataset
Found at doi:10.1371/journal.pcbi.0030030.st001 (2.5 MB XLS).
Table S2. PPARa Rat Liver Dataset
Found at doi:10.1371/journal.pcbi.0030030.st002 (6.9 MB XLS).
Table S3. Liver Hypertrophy Training Dataset
Found at doi:10.1371/journal.pcbi.0030030.st003 (117 KB XLS).
Table S4. Liver Hypertrophy Testing Dataset
Found at doi:10.1371/journal.pcbi.0030030.st004 (67 KB XLS).
Accession Numbers
Gene ID numbers from the Entrez Gene database (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db¼gene) for the genes mentioned in
this paper are: Acac (31), Acadl (33), Acadm (34), Apoa4 (337), Cdc2a
(12534), Cpt1a (1374), Golga4 (2803), Lpin2 (9663), Nrli3 (9970), Pck1
(5105), Pex19 (5824), Pitrm1 (69617), Ppara (5465), Scd1 (20249),
2010309E21Rik (66488), 2700017I06Rik (209630), 3110048E14Rik
(73225), and 9430083G14Rik (68817).
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